Publication: Estudio de utilización de la pirfenidona en fibrosis pulmonar idiopática
Loading...
Official URL
Full text at PDC
Publication Date
2017-02
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Citations
Exportar
Abstract
La Fibrosis Pulmonar Idiopática (FPI) se suele caracterizar por ser una enfermedad de transcurso lento. No es fácil diagnosticarla debido a que otras patologías respiratorias pueden enmascarar o confundir su identificación. Es por ello, que para conseguir un correcto diagnóstico de la FPI, es necesario realizar tanto una Tomografía axial Computarizada de Alta Resolución (TCAR), como una biopsia pulmonar. De entre los fármacos usados para tratarla, la pirfenidona es un fármaco que tiene la indicación autorizada para esta patología. Estudios como CAPACITY demostraron una mejoría en el pronóstico de la FPI, así como una disminución en el riesgo de muerte. Este trabajo se encarga de estudiar la eficacia y seguridad de la pirfenidona en pacientes diagnosticados de FPI en un hospital de tercer nivel. Este pequeño estudio concluye que la pirfenidona es eficaz en un 87,5% de los pacientes afectados con FPI en el Hospital Universitario Gregorio Marañón al cabo de un año de tratamiento, ya que mantiene parámetros clínicos de su enfermedad estables, demostrando así su eficacia. Cabe destacar, que solo en un 12,5% de los pacientes muestra intolerancia al medicamento, por lo que también es un fármaco muy seguro.
Idiopathic Pulmonary Fibrosis (IPF) is characterized by being a slow-progress disease. It’s not easy to diagnose it because other respiratory pathologies can cover or confuse its identification. Therefore, to achieve a correct diagnosis of IPF, it is necessary to perform both a High Resolution Computed Tomography (HRCT) and a pulmonary biopsy. Among all the drugs used to treat it, pirfenidone is a drug that has the authorized indication for this pathology. Studies such as CAPACITY showed an improvement in the prognosis of IPF, as well as a decrease in the risk of death. This work is responsible for studying the efficacy and safety of pirfenidone in patients diagnosed with IPF in a third-level hospital. This small study concludes that pirfenidone is effective in 87.5% of patients affected by IPF at the Hospital Universitario Gregorio Marañón after one year of treatment as it maintains the clinical parameters of its disease stable, thus demonstrating its efficacy. To highlight only 12.5% of patients show intolerance, so it is also a very safe drug.
Idiopathic Pulmonary Fibrosis (IPF) is characterized by being a slow-progress disease. It’s not easy to diagnose it because other respiratory pathologies can cover or confuse its identification. Therefore, to achieve a correct diagnosis of IPF, it is necessary to perform both a High Resolution Computed Tomography (HRCT) and a pulmonary biopsy. Among all the drugs used to treat it, pirfenidone is a drug that has the authorized indication for this pathology. Studies such as CAPACITY showed an improvement in the prognosis of IPF, as well as a decrease in the risk of death. This work is responsible for studying the efficacy and safety of pirfenidone in patients diagnosed with IPF in a third-level hospital. This small study concludes that pirfenidone is effective in 87.5% of patients affected by IPF at the Hospital Universitario Gregorio Marañón after one year of treatment as it maintains the clinical parameters of its disease stable, thus demonstrating its efficacy. To highlight only 12.5% of patients show intolerance, so it is also a very safe drug.